245 related articles for article (PubMed ID: 27404349)
41. Inhibition of topoisomerase IIalpha expression by transforming growth factor-beta1 is abrogated by the papillomavirus E7 protein.
Satterwhite DJ; White RL; Matsunami N; Neufeld KL
Cancer Res; 2000 Dec; 60(24):6989-94. PubMed ID: 11156401
[TBL] [Abstract][Full Text] [Related]
42. Casein kinase II stabilizes the activity of human topoisomerase IIalpha in a phosphorylation-independent manner.
Redwood C; Davies SL; Wells NJ; Fry AM; Hickson ID
J Biol Chem; 1998 Feb; 273(6):3635-42. PubMed ID: 9452492
[TBL] [Abstract][Full Text] [Related]
43. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
44. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells.
Hossain MS; Akimitsu N; Takaki T; Hirai H; Sekimizu K
Genes Cells; 2002 Mar; 7(3):285-94. PubMed ID: 11918672
[TBL] [Abstract][Full Text] [Related]
45. DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
Nakopoulou L; Lazaris AC; Kavantzas N; Alexandrou P; Athanassiadou P; Keramopoulos A; Davaris P
Pathobiology; 2000; 68(3):137-43. PubMed ID: 11174071
[TBL] [Abstract][Full Text] [Related]
46. The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.
Engel R; Valkov NI; Gump JL; Hazlehurst L; Dalton WS; Sullivan DM
Exp Cell Res; 2004 May; 295(2):421-31. PubMed ID: 15093741
[TBL] [Abstract][Full Text] [Related]
47. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
Davies SL; Bergh J; Harris AL; Hickson ID
Br J Cancer; 1997; 75(6):816-21. PubMed ID: 9062401
[TBL] [Abstract][Full Text] [Related]
48. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast.
Nakazawa N; Arakawa O; Ebe M; Yanagida M
J Biol Chem; 2019 Mar; 294(10):3772-3782. PubMed ID: 30635402
[TBL] [Abstract][Full Text] [Related]
49. A withanolide coagulin-L inhibits adipogenesis modulating Wnt/β-catenin pathway and cell cycle in mitotic clonal expansion.
Beg M; Chauhan P; Varshney S; Shankar K; Rajan S; Saini D; Srivastava MN; Yadav PP; Gaikwad AN
Phytomedicine; 2014 Mar; 21(4):406-14. PubMed ID: 24252344
[TBL] [Abstract][Full Text] [Related]
50. Regulation of catalytic activity and nucleolar localization of rat DNA topoisomerase IIα through its C-terminal domain.
Yasuda K; Kato Y; Ikeda S; Kawano S
Genes Genet Syst; 2021 Mar; 95(6):291-302. PubMed ID: 33551432
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Kitdumrongthum S; Reabroi S; Suksen K; Tuchinda P; Munyoo B; Mahalapbutr P; Rungrotmongkol T; Ounjai P; Chairoungdua A
Biomed Pharmacother; 2020 Jul; 127():110149. PubMed ID: 32344256
[TBL] [Abstract][Full Text] [Related]
52. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of mitotic clonal expansion mediates fisetin-exerted prevention of adipocyte differentiation in 3T3-L1 cells.
Lee Y; Bae EJ
Arch Pharm Res; 2013 Nov; 36(11):1377-84. PubMed ID: 23918651
[TBL] [Abstract][Full Text] [Related]
54. Evidence for a critical role of DNA topoisomerase IIalpha in drug sensitivity revealed by inducible antisense RNA in a human leukaemia cell line.
Towatari M; Adachi K; Marunouchi T; Saito H
Br J Haematol; 1998 Jun; 101(3):548-51. PubMed ID: 9633900
[TBL] [Abstract][Full Text] [Related]
55. Two differentially spliced forms of topoisomerase IIalpha and beta mRNAs are conserved between birds and humans.
Petruti-Mot AS; Earnshaw WC
Gene; 2000 Nov; 258(1-2):183-92. PubMed ID: 11111056
[TBL] [Abstract][Full Text] [Related]
56. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
Oloumi A; MacPhail SH; Johnston PJ; Banáth JP; Olive PL
Cancer Res; 2000 Oct; 60(20):5747-53. PubMed ID: 11059769
[TBL] [Abstract][Full Text] [Related]
57. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
58. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
[TBL] [Abstract][Full Text] [Related]
59. Dynamic behavior of DNA topoisomerase IIβ in response to DNA double-strand breaks.
Morotomi-Yano K; Saito S; Adachi N; Yano KI
Sci Rep; 2018 Jul; 8(1):10344. PubMed ID: 29985428
[TBL] [Abstract][Full Text] [Related]
60. Co-localization of chicken DNA topoisomerase IIalpha, but not beta, with sites of DNA replication and possible involvement of a C-terminal region of alpha through its binding to PCNA.
Niimi A; Suka N; Harata M; Kikuchi A; Mizuno S
Chromosoma; 2001 May; 110(2):102-14. PubMed ID: 11453553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]